Overview

HLA Genotyping for Safer Transplants and Personalized Care: Human Leukocyte Antigen (HLA) typing identifies specific HLA proteins on cell surfaces, critical markers that help the immune system distinguish self from foreign cells. The HLA system is fundamental to immune defense, enabling T cells to detect and respond to foreign antigens with precision. Highly polymorphic, with thousands of alleles identified, HLA genes influence disease defense, cancer susceptibility, and adverse drug reactions and are the leading cause of organ transplant rejection. Accurate, high-resolution HLA typing is essential for transplantation compatibility, disease association studies, and population genetics. Next-Generation Sequencing (NGS) has revolutionized HLA genotyping, delivering unmatched precision and reliability for identifying genetic variations. By leveraging NGS-based HLA typing, clinicians and researchers can ensure better transplant outcomes, uncover disease risk markers, and advance personalized medicine.

The HLA region, which is the most densely polymorphic region of the genome, can be sequenced accurately with our HLA typing NGS assay. The genomic DNA sample from blood is considered for library preparation and enrichment that further can be sequenced on NGS sequencer. Genes2Me’s HLA Typing NGS Assay generates unambiguous, phase-resolved results with critical insights into immune disorders, powered by advanced hybridization capture-based target enrichment for unmatched accuracy. It is a high-resolution allele identification and precision diagnostic assay that aids in the selection of the best donor for the recipient. DNA extracted from the blood of transplant recipients & donors is evaluated for histocompatibility antigens targeting 11 loci such as Class-1 HLA-A, B, C; Class II: HLA DPA1, DPB1, DQA1, DAQB1, DRB1/3/4/5. This panel targets the coding region compiling to the size of ~71kb.